So far, the epigenetic regulation with particular focus on DNA promoter methylation of the PD-L2 encoding gene, PDCD1LG2, has not been considered as a biomarker in the context of anti-PD-1 immunotherapies in melanoma. Here, PDCD1LG2 is linked to melanoma.